EFFICACY OF INTRACAMERAL BEVACIZUMAB INJECTION WITH AND WITHOUT PANRETINAL PHOTOCOAGULATION IN MANAGEMENT OF NEOVASCULAR GLAUCOMA

Objective: To evaluate the efficacy and safety of intracameral bevacizumab with and without panretinal photocoagulation in treating neovascular glaucoma. Method: This prospective interventional case series included fifty eyes of fifty patients were included in this study; twenty five eyes with neovascular glaucoma were treated with one dose of 2.5 mg intracameral bevacizumab only (group I) while other twenty five eyes were treated with one dose of 2.5 mg intracameral bevacizumab and laser panretinal photocoagulation (group II). Results: The study showed that there was no statistical difference regarding visual acuity in group I (P>0.05), while there is a highly significant difference in group II (P 0.05), while there is a highly significant difference in group II (P <0.001). Conclusions: Intracameral bevacizumab and laser panretinal photocoagulation is more effective in treatment of NVG in terms of angle neovascularization regression and IOP control.